Zevra Therapeutics ZVRA
NASDAQ ZVRA
$12.40 -0.14 (-1.12%)
As of: Sep 4, 2026 · 3:59 PM EDT

Zevra Therapeutics (ZVRA) EBT Margin Growth (3y) (2022 - 2026)

Analysis

Zevra Therapeutics (ZVRA) EBT Margin Growth (3y) (2022 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -484.00
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 132.00
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 6,691.00
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -2,054.00
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 8,006.00
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 9,980.00
8 Royalty Pharma 28.45 Bn 27.61 Bn - -5,319.00
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 31,363.00
10 Zevra Therapeutics 734.60 Mn 513.03 Mn 38.18 Mn 6,348.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 6,348.00
Mar 31, 2026 54,310.00
Dec 31, 2025 -28,285.00
Sep 30, 2025 22,761.00
Jun 30, 2025 220,132.00
Mar 31, 2025 3,772.00
Dec 31, 2024 -6,619.00
Sep 30, 2024 -80,846.00
Jun 30, 2024 -49,803.00
Mar 31, 2024 -40,239.00
Dec 31, 2023 5,153.00
Sep 30, 2023 -19,391.00
Jun 30, 2023 -4,369.00
Mar 31, 2023 -14,395.00
Dec 31, 2022 75,925.00
Sep 30, 2022 -25,810.00